Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus

Меснянкина А. А., Соловьев С. К., Асеева Е. А., Насонов Е. Л.
Научно-практическая ревматология
Т. 56, Вып. 3, С. 302-309
Опубликовано: 2018
Тип ресурса: Статья

DOI:10.14412/1995-4484-2018-302-309

Аннотация:
Objective: to investigate the effect of various biological agents (BAs), including combined treatment with rituximab (RTM) and belimumab (BLM), on the activity of systemic lupus erythematosus (SLE) and to evaluate their efficacy and impact on some parameters of humoral immunity. Subjects and methods. BAs were prescribed to 54 patients with a reliable diagnosis of SLE with high and medium activity according to SLEDAI-2K; 40 of them received RTM, 7 – BLM; 7 – combined therapy with RTM and BLM. Clinical and laboratory examinations were made in all the patients at the time of their inclusion and then every 3 months during a year. The results were assessed using SLEDAI-2K, BILAG index, Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare index (SFI) (a moderate, severe exacerbation), and SLE Responder Index (SRI). Results and discussion. At 3, 6, and 12 months after start of therapy, the use of BAs in all the patients resulted in a disease activity reduction. It was statistically s
Ключевые слова:
Belimumab; Biological agents; Rituximab; Systemic lupus erythematosus; Treatment
Язык текста: Русский
ISSN: 1995-4492
Меснянкина А. А.
Соловьев С. К.
Асеева Е. А.
Насонов Е. Л. Евгений Львович 1948-
Mesnyankina A. A.
Solovyev S. K.
Aseeva E. A.
Nasonov E. L. Evgenij L`vovich 1948-
The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 3 С. 302-309
2018
Статья
Belimumab Biological agents Rituximab Systemic lupus erythematosus Treatment
Objective: to investigate the effect of various biological agents (BAs), including combined treatment with rituximab (RTM) and belimumab (BLM), on the activity of systemic lupus erythematosus (SLE) and to evaluate their efficacy and impact on some parameters of humoral immunity. Subjects and methods. BAs were prescribed to 54 patients with a reliable diagnosis of SLE with high and medium activity according to SLEDAI-2K; 40 of them received RTM, 7 – BLM; 7 – combined therapy with RTM and BLM. Clinical and laboratory examinations were made in all the patients at the time of their inclusion and then every 3 months during a year. The results were assessed using SLEDAI-2K, BILAG index, Lupus Erythematosus National Assessment (SELENA)-SLEDAI Flare index (SFI) (a moderate, severe exacerbation), and SLE Responder Index (SRI). Results and discussion. At 3, 6, and 12 months after start of therapy, the use of BAs in all the patients resulted in a disease activity reduction. It was statistically s